Insignificant Prostate Cancer and Active Surveillance: From Definition to Clinical Implications

被引:138
作者
Bastian, Patrick J. [1 ]
Carter, Ballentine H. [4 ]
Bjartell, Anders [3 ]
Seitz, Michael [1 ]
Stanislaus, Peter [1 ]
Montorsi, Francesco [5 ]
Stief, Christian G. [1 ]
Schroeder, Fritz [2 ]
机构
[1] Univ Klinikun Univ Munchen Grosshadern, Urol Klin & Poliklin, Munich, Germany
[2] Univ Med Ctr, Erasmus MC, Rotterdam, Netherlands
[3] Lund Univ, Dept Clin Sci, Div Urol Canc, Malmo, Sweden
[4] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD USA
[5] Univ Vita Salute San Raffaele, I-20132 Milan, Italy
关键词
Prostate cancer; Active surveillance; Watchful waiting; Insignificant prostate cancer; Low risk prostate cancer; QUALITY-OF-LIFE; SELECTIVE DELAYED INTERVENTION; GSTP1 CPG ISLAND; RADICAL PROSTATECTOMY; CONSERVATIVE MANAGEMENT; EXPECTANT MANAGEMENT; CURATIVE INTENT; ANTIGEN; RISK; MEN;
D O I
10.1016/j.eururo.2009.02.028
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Context: Due to early detection strategies, prostate cancer is diagnosed early in its natural history. It remains unclear whether all patients diagnosed with prostate cancer warrant radical treatment or may benefit from delayed intervention following active surveillance. Objective: A systematic review of active surveillance protocols to investigate the inclusion criteria for active surveillance and the outcome of treatment. Evidence acquisition: Medline was searched using the following terms: prostate cancer, active surveillance and expectant management for dates up to October 2008. Further studies were chosen on the basis of manual searches of reference lists and review papers. Evidence synthesis: Numerous studies on active surveillance were identified. The recent inclusion criteria of the studies are rather similar. Keeping the short follow-up of all studies in mind, the majority of men stay on active surveillance, and the percentage of patients receiving active treatment is as high as 35% of all patients. Once a patients requires active treatment, most patients still present with curable prostate cancer. Furthermore, only few deaths due to prostate cancer have occurred. Conclusions: Active surveillance is an alternative option to immediate treatment of men with presumed insignificant prostate cancer. It seems that criteria used to identify men with low-risk prostate cancer are rather similar, and immediate treatment of men meeting these criteria may result in an unnecessary number of treatments in these highly selected patients. Data from randomised trials comparing active surveillance and active treatment will provide additional insight into outcome and follow-up strategies. (C) 2009 Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:1321 / 1332
页数:12
相关论文
共 76 条
[1]   20-year outcomes following conservative management of clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Fine, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101
[2]   PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer:: Results from the European randomized study of screening for prostate cancer, Sweden section [J].
Ali, Khatami ;
Gunnar, Aus ;
Jan-Erik, Damber ;
Hans, Lija ;
Par, Lodding ;
Jonas, Hugosson .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (01) :170-174
[3]   Watching, waiting and uncertainty in prostate cancer [J].
Bailey, Donald E., Jr. ;
Wallace, Meredith ;
Mishel, Merle H. .
JOURNAL OF CLINICAL NURSING, 2007, 16 (04) :734-741
[4]   What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance?: An analysis of the CaPSURE™ database [J].
Barocas, Daniel A. ;
Cowan, Janet E. ;
Smith, Joseph A. ;
Carroll, Peter R. .
JOURNAL OF UROLOGY, 2008, 180 (04) :1330-1334
[5]   Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy [J].
Bastian, PJ ;
Palapattu, GS ;
Lin, XH ;
Yegnasubramanian, S ;
Mangold, LA ;
Trock, B ;
Eisenberger, MA ;
Partin, AW ;
Nelson, WG .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4037-4043
[6]   Characteristics of insignificant clinical T1c prostate tumors - A contemporary analysis [J].
Bastian, PJ ;
Mangold, LA ;
Epstein, JI ;
Partin, AW .
CANCER, 2004, 101 (09) :2001-2005
[7]   Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience [J].
Carter, H. Ballentine ;
Kettermann, Anna ;
Warlick, Christopher ;
Metter, E. Jeffrey ;
Landis, Patricia ;
Walsh, Patrick C. ;
Epstein, Jonathan I. .
JOURNAL OF UROLOGY, 2007, 178 (06) :2359-2364
[8]   Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability [J].
Carter, H. Ballentine ;
Ferrucci, Luigi ;
Kettermann, Anna ;
Landis, Patricia ;
Wright, E. James ;
Epstein, Jonathan I. ;
Trock, Bruce J. ;
Metter, E. Jeffrey .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (21) :1521-1527
[9]   Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results [J].
Carter, HB ;
Walsh, PC ;
Landis, P ;
Epstein, JI .
JOURNAL OF UROLOGY, 2002, 167 (03) :1231-1234
[10]   Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease - A prospective multicenter clinical trial [J].
Catalona, WJ ;
Partin, AW ;
Slawin, KM ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
deKernion, JB ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Subong, ENP ;
Parson, RE ;
Gasior, GH ;
Loveland, KG ;
Southwick, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1542-1547